Clinical observation of sarcandra glabra combined chemoradiotherapy for treating patients with local advanced nasopharyngeal carcinoma / 中国中西医结合杂志

<p><b>OBJECTIVE</b>To observe the short-term efficacy and radiotherapy induced acute reactions of sarcandra glabra (SG) combined chemoradiotherapy for treating patients with local advanced nasopharyngeal carcinoma.</p><p><b>METHODS</b>Totally 100 nasopharyngeal carcinoma phase III - IVa patients were randomly assigned to the control group and the observation group, 50 patients in each group. All patients received chemoradiotherapy. Patients in the observation group took SG decoction at the daily dose of 20 g.</p><p><b>RESULTS</b>Totally 98 patients completed the treatment. There was no statistical difference in the complete remission rate, the partial remission rate, 1-year and 2-year total survival rates, or disease free progression rate between the two groups. The occurrence rate of II - III degree radioactive oral mucositis and dry mouth were obviously lower in the observation group than in the control group, showing statistical difference (P <0.05).</p><p><b>CONCLUSION</b>SG combined chemoradiotherapy could attenuate radiotherapy induced acute adverse reactions in treating advanced nasopharyngeal carcinoma.</p>

Clinical observation on treatment of 75 mid-late stage cancer patients with yanshu Injection / 中国中西医结合杂志

<p><b>OBJECTIVE</b>To study the effect of Yanshu Injection (YI) used in comprehensive treatment on mid-late stage cancer.</p><p><b>METHODS</b>One hundred and fifty patients with malignant cancer were equally randomized into the comprehensive treatment group (group A) and the control group (group B), both groups were treated systematically according to the NCCN 2005 cancer practice guideline, but 20 ml of YI was given additionally to group A every day.</p><p><b>RESULTS</b>After treatment, the level of plasma CD4 and CD4/CD8 ratio were significantly lower in group B than those in group A (P < 0.05); the response rate (RR) was 32.00% (24/75) and 38.67% (29/75) in group B and A respectively, showing insignificant difference (P>0.05), and the clinical benefit rate (CBR)was 58.67% (44/75) in group A, lower than that in group B (85.33% (64/75), P< 0.05); the quality of life (QOL) in group A was superior to that in group B (P<0.05); and the incidence of main adverse reaction to chemotherapeutic agents was significantly lower in group A as compared to that in group B (P<0.05).</p><p><b>CONCLUSION</b>YI could regulate the function of T-lymphocyte subsets, raise the CBR and QOL and reduce adverse reaction of chemotherapy in patients with mid-late stage cancer.</p>